Cargando…

Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review

The management of multidrug-resistant human immunodeficiency virus (MDR HIV) infections in children is particularly challenging due to the lack of experience with new drugs. Dolutegravir, combined with an optimized antiretroviral background therapy, is promising for the treatment of MDR HIV and has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner, N., Wyler-Lazarevic, C.A., Yerly, S., Samer, C., Peytavin, G., Posfay-Barbe, K.M., Calmy, A., Ambrosioni, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Mini-Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430707/ https://www.ncbi.nlm.nih.gov/pubmed/26082840 http://dx.doi.org/10.1016/j.nmni.2015.02.003

Ejemplares similares

Corrigendum to “Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review” [New Microbes New Infect] 6 (2015) 1–4]
por: Wagner, N., et al.
Publicado: (2015)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
por: Hailu, Workagegnehu, et al.
Publicado: (2021)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy
por: Nakaharai, Kazuhiko, et al.
Publicado: (2017)

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus
por: Hirigo, Agete Tadewos, et al.
Publicado: (2022)

Viral Escape in the Central Nervous System with Multidrug-Resistant Human Immunodeficiency Virus-1
por: Béguelin, C., et al.
Publicado: (2015)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model
por: Mandelbrot, Laurent, et al.
Publicado: (2019)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Mathematical Modeling of HIV Dynamics After Antiretroviral Therapy Initiation: A Review
por: Rivadeneira, Pablo S., et al.
Publicado: (2014)

Molecular Dynamics Computer Simulations of Multidrug RND Efflux Pumps
por: Ruggerone, Paolo, et al.
Publicado: (2013)

Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients
por: Göhring, Katharina, et al.
Publicado: (2015)

Congenital syphilis in 2 children in a Bolivian prison
por: Gétaz, L., et al.
Publicado: (2017)

Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
por: Christensen, Erin S., et al.
Publicado: (2017)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients
por: Punekar, Yogesh Suresh, et al.
Publicado: (2019)

Isotopic Radiolabeling of the Antiretroviral Drug [(18)F]Dolutegravir for Pharmacokinetic PET Imaging
por: Tisseraud, Marion, et al.
Publicado: (2022)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
por: Mahomed, Kairoonisha, et al.
Publicado: (2020)

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study
por: Hauser, Anthony, et al.
Publicado: (2020)

The role of dietary sugars, overweight, and obesity in type 2 diabetes mellitus: a narrative review
por: Veit, Meike, et al.
Publicado: (2022)

HIV treatment for prevention
por: Ambrosioni, Juan, et al.
Publicado: (2011)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
por: Huang, Chang, et al.
Publicado: (2023)

Transient elevation of humoral responses against apolipoprotein A-1 following COVID-19 and its association with symptoms persistence
por: L'Huillier, A.G., et al.
Publicado: (2022)

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
por: Kanters, Steve, et al.
Publicado: (2020)

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
por: Khemla, Supphachoke, et al.
Publicado: (2023)

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
por: Phillips, Andrew N, et al.
Publicado: (2020)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

The effects of Transcranial Direct Current Stimulation on food craving and food intake in individuals affected by obesity and overweight: a mini review of the magnitude of the effects
por: Orrù, Graziella, et al.
Publicado: (2022)

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications
por: Wilson, Herieth Ismael, et al.
Publicado: (2020)

Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir
por: Belfrage, Erik, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hlhr12t6eod2etp7qec0sbejmf